Speaking in the video, which was posted on The Royal Family’s Facebook account, he said: “It’s normal for me, even though I’m not from this part of London or being the person that I am and the people I am sitting around, I am still here being tested”. While the rate of annual death from HIV/AIDS has been in a steady decline from a peak of 1.8 million in 2005 to 1.2 million in 2015.
Advertisement
While the annual number of new infections has decreased since its peak at 3.3 million per year in 1997, it has stayed relatively constant at around an estimated 2.5 million a year worldwide for the past decade.
The study shows that while 28.81 lakh people were living with HIV infection in India previous year, 1.31 lakh people in the country died of HIV/AIDS in 2015.
The study is based on findings from the Global Burden of Diseases, Injuries, and Risk Factors Study and explored the numbers of new infections, people living with HIV, deaths from HIV infection and people accessing treatment in 195 countries and territories from 2005 to 2015.
The proportion of people living with HIV on ART increased rapidly between 2005 and 2015, from 6.4 per cent to 38.6 per cent for men and from 3.3 per cent to 42.4 per cent for women. In 2015, half of new infections among children (0-14 years), occurred in only six countries: Nigeria, India, Kenya, Mozambique, Tanzania and South Africa.
Within Europe, the highest number of new infections in 2015 were in Russian Federation (57340), Ukraine (13490), Spain (2350), Portugal (2220), United Kingdom (2060), Italy (1960), and Germany (1760; table).
No country has achieved the UNAIDS 90-90-90 target that 81 percent of people living with HIV should be receiving ART by 2020 yet, Sweden (76 percent), the USA, Netherlands, and Argentina (all at about 70 percent) are close.
Although global HIV mortality has been declining at 5.5% a year since the mid-2000s, progress has been mixed between regions and countries (figure 1C).
In 2014 alone, as many as 150,000 children under the age of 15 with HIV died of opportunistic infections in low-to-middle income countries. After modifying the dosage and tuning the vaccine to protect against HIV’s Clade C subtype more common to sub-Saharan Africa, researchers began conducting HVTN 100 in South Africa in 2015.
Advertisement
That study, in turn, was prompted by a 2009 trial in Thailand with a 60 percent rate of protection against the virus after one year and a 31 percent rate at the end of the trial – the first to ever show any signs of success.
